Project Grant K08CA304375
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $442,750.00 to New York University (NYU) to conduct a study on implementation strategies for cervical cancer control policies in Africa. The project aims to: (A) Engage a network of experts from African low- and middle-income countries (LMICs) and global agencies through a Delphi process to identify determinants of policy implementation success, using the Consolidated...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $403,383 to the Medstar Health Research Institute Inc. to develop and pilot test a new virtual reality (VR)-based therapy that integrates cognitive behavioral strategies to help manage chronic cancer pain. The research aims to create an evidence-based, patient-centered VR intervention that can serve as a non-pharmacologic complement to opioid therapies for cancer patients...
- This federal Project Grant award of $312,892 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research at Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to understand how ILC3s impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients, as the majority do not respond to ICI treatment....
- This $3,355,681 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to evaluate the impact of accessible and scalable digital interventions to address co-occurring insomnia and depression in breast cancer survivors. The project will assess the efficacy of two evidence-based digital interventions, SHUTI and INTELLICARE, in treating these conditions both individually and through an adaptive approach that sequences the interventions based...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...
- This $161,000 federal Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at Duke University to investigate "Breast Cancer Brain Metastases: Integrating Immunogenomic and Phenotypic Vulnerabilities to Improve Outcomes." The research aims to develop innovative approaches to understand complex biological systems, create new diagnostic tools, and explore potential therapeutic interventions...
- The federal Project Grant award of $135,990.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a cross-sectional, comparative research study at the University of Illinois. The study aims to investigate cognition, vascular function, and physical activity levels in colorectal cancer survivors compared to matched controls. The key objectives are to: (1) compare cognitive processing speed, carotid-femoral pulse wave velocity, and moderate-to-vigorous physical...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $155,156 to support an 8-week, home-based, virtually supervised prehabilitative exercise intervention for 30 multiple myeloma patients undergoing autologous stem cell transplantation at the Dana-Farber Cancer Institute. The primary objectives are to examine the effects of this exercise program on muscle strength, patient health outcomes, and clinical outcomes. The award period runs...
- The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $413,971 Project Grant to Duke University to develop and pilot test a novel nurse navigator-delivered intervention for women experiencing premature or early menopause after cancer treatment. The intervention will integrate personalized menopause education, decision support, skills to improve self-management, and cognitive behavioral techniques to manage menopausal...
This Project Grant award of $178,453 from the National Cancer Institute (CFDA Program 93.398 - Cancer Research Manpower) aims to develop and pilot test a novel behavioral intervention to enhance engagement with vaginal dilator therapy among female cancer survivors who underwent pelvic radiation therapy. The grant will fund a three-phase study, including qualitative interviews to inform intervention development, user testing to refine the intervention, and an examination of the feasibility and acceptability of the intervention. Key outcomes to be assessed include changes in the frequency and duration of dilator use, as well as impacts on symptom burden, emotional distress, and dilator therapy knowledge. The award is held by Duke University's Office of Research Administration and will be performed in North Carolina. The project period runs from August 8, 2025 through July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $178.5k | 8/7/25 |